Transforming the treatment of fibrosis

New anti-fibrotic therapies based on breakthrough science

Our Mission

Fibrotic diseases are a major burden on human health, afflicting millions of people every year with few treatment options available.

Our mission is to create new anti-fibrotic therapies based on breakthrough science.

null

Pulmonary Fibrosis

null

Cardiomyopathy & Heart Failure

null

Atrial Fibrillation

null

Non-alcoholic Steatohepatitis

null

Chronic Kidney Disease

null

Inflammatory Bowel Disease

null

Scleroderma

We are developing first-in-class antibody therapeutics to treat fibrosis.

Our Focus

null

Human-based genetic & genomic discovery

null

Cutting edge human fibrosis assays

null

Excellent models of human disease

null

Strong human genetic data supporting drug safety

Our Products

null

Cytokine Antibody

Phage display based on a human naive antibody library

null

Receptor Antibody

Genetic immunisation of mice and antibody humanisation

null

Decoy Receptor

Soluble receptors to inhibit cytokine signalling

null

siRNA

Specific inhibition of signalling using siRNA technology

Integrated human discovery and efficacy screening pipelines for all our products.

Read More

null

Our Team

null

Latest News